INT103471

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2002
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 4
Total Number 7
Disease Relevance 4.25
Pain Relevance 1.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (BDNF) cytoplasmic membrane-bounded vesicle (BDNF)
Anatomy Link Frequency
hippocampus 6
BDNF (Homo sapiens)
Pain Link Frequency Relevance Heat
Hippocampus 36 99.68 Very High Very High Very High
antidepressant 174 99.42 Very High Very High Very High
depression 175 94.64 High High
Nerve growth factor 5 88.24 High High
tolerance 5 87.28 High High
Glutamate receptor 3 75.00 Quite High
Neurotransmitter 33 71.12 Quite High
tetrodotoxin 1 59.28 Quite High
monoamine 39 50.20 Quite High
Serotonin 24 34.08 Quite Low
Disease Link Frequency Relevance Heat
Stress 77 99.44 Very High Very High Very High
Depression 256 99.30 Very High Very High Very High
Death 13 96.82 Very High Very High Very High
Frailty 6 96.12 Very High Very High Very High
Neurodegenerative Disease 26 95.04 Very High Very High Very High
Depressive Disorder 147 88.56 High High
Affective Disorder 5 71.72 Quite High
Traumatic Stress Disorders 3 42.56 Quite Low
Anxiety Disorder 5 41.12 Quite Low
Neurological Disease 12 40.12 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Second, in most cases, the usage of alternative promoters in the human BDNF gene leads to the expression of transcripts with different 5?
Positive_regulation (leads) of Transcription (usage) of BDNF
1) Confidence 0.44 Published 2007 Journal Genomics Section Body Doc Link PMC2568880 Disease Relevance 0 Pain Relevance 0
Our results show that the expression of antiBDNF and BDNF transcripts in different tissues is not mutually exclusive and that the levels of BDNF mRNA do not appear to be specifically reduced in tissues that express high levels of antiBDNF transcripts.
Neg (not) Spec (appear) Positive_regulation (appear) of Transcription (levels) of BDNF
2) Confidence 0.44 Published 2007 Journal Genomics Section Body Doc Link PMC2568880 Disease Relevance 0 Pain Relevance 0.04
While total BDNF mRNA levels are unchanged, BDNF transcripts 1c and 1d resulted down regulated after acute stress.
Neg (unchanged) Positive_regulation (unchanged) of Transcription (levels) of BDNF associated with stress
3) Confidence 0.42 Published 2010 Journal BMC Neurosci Section Abstract Doc Link PMC2829032 Disease Relevance 0.80 Pain Relevance 0
Key observations leading to and strengthening this theory are: (1) neurotrophic factors, especially BDNF and VEGF, are under-expressed in limbic structures implicated in depression (especially the hippocampus) and may contribute to their observed atrophy and increased sensitivity to death (Sapolsky, 2000; Duman and Monteggia, 2006); (2) HPA-axis dysfunction exacerbates this phenomenon, while effective antidepressant treatments counteract it by enhancing hippocampal BDNF mRNA expression through the cAMP-CREB cascade (Duman et al., 1997, 2000); and (3) ECT and MAOI antidepressants, considered to be the most effective at relieving depressive symptoms, were shown to most significantly increase BDNF and trkB (the BDNF receptor) mRNA expression in the hippocampus (Nibuya et al., 1995).


Positive_regulation (increase) of Transcription (expression) of BDNF in hippocampus associated with antidepressant, depression, frailty, hippocampus and death
4) Confidence 0.36 Published 2010 Journal Frontiers in Neuroengineering Section Body Doc Link PMC2901135 Disease Relevance 1.18 Pain Relevance 0.46
Key observations leading to and strengthening this theory are: (1) neurotrophic factors, especially BDNF and VEGF, are under-expressed in limbic structures implicated in depression (especially the hippocampus) and may contribute to their observed atrophy and increased sensitivity to death (Sapolsky, 2000; Duman and Monteggia, 2006); (2) HPA-axis dysfunction exacerbates this phenomenon, while effective antidepressant treatments counteract it by enhancing hippocampal BDNF mRNA expression through the cAMP-CREB cascade (Duman et al., 1997, 2000); and (3) ECT and MAOI antidepressants, considered to be the most effective at relieving depressive symptoms, were shown to most significantly increase BDNF and trkB (the BDNF receptor) mRNA expression in the hippocampus (Nibuya et al., 1995).


Positive_regulation (increase) of Transcription (expression) of BDNF in hippocampus associated with antidepressant, depression, frailty, hippocampus and death
5) Confidence 0.36 Published 2010 Journal Frontiers in Neuroengineering Section Body Doc Link PMC2901135 Disease Relevance 1.18 Pain Relevance 0.46
Key observations leading to and strengthening this theory are: (1) neurotrophic factors, especially BDNF and VEGF, are under-expressed in limbic structures implicated in depression (especially the hippocampus) and may contribute to their observed atrophy and increased sensitivity to death (Sapolsky, 2000; Duman and Monteggia, 2006); (2) HPA-axis dysfunction exacerbates this phenomenon, while effective antidepressant treatments counteract it by enhancing hippocampal BDNF mRNA expression through the cAMP-CREB cascade (Duman et al., 1997, 2000); and (3) ECT and MAOI antidepressants, considered to be the most effective at relieving depressive symptoms, were shown to most significantly increase BDNF and trkB (the BDNF receptor) mRNA expression in the hippocampus (Nibuya et al., 1995).


Positive_regulation (enhancing) of Transcription (expression) of BDNF in hippocampus associated with antidepressant, depression, frailty, hippocampus and death
6) Confidence 0.33 Published 2010 Journal Frontiers in Neuroengineering Section Body Doc Link PMC2901135 Disease Relevance 1.08 Pain Relevance 0.53
K252a, a specific tyrosine kinase (Trk) inhibitor, completely suppresses BDNF- and NT-4/5-enhanced BDNF mRNA expression.
Positive_regulation (enhanced) of Transcription (expression) of BDNF
7) Confidence 0.12 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12069900 Disease Relevance 0 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox